adesso (ADN1) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
5 Jun, 2025Executive summary
Achieved group sales of €1.3 billion in 2024, up 14% year-over-year, driven almost entirely by organic growth and international expansion.
EBITDA rose 23% to €98.3 million (excluding one-off effects), with margin improvement to 7.6% and H2 margin at 10.6%.
Consolidated earnings increased to €10.2 million; earnings per share up 155% to €1.25.
Share buyback program completed, repurchasing 1.9% of share capital for €10 million.
Workforce grew by 12% on average, with year-end headcount growth slowing to 8% due to a hiring freeze.
Financial highlights
Sales grew 14% year-over-year to €1,297.0 million in 2024, driven by organic growth.
EBITDA margin improved to 7.6% (excluding one-off effects); operating cash flow up 44% to €110.6 million.
Free cash flow reached €45.1 million, up 217% year-over-year, and free cash flow per share improved to €6.92.
Net debt at €46.6 million, decreased slightly by €2 million; net working capital reduced by 8% to €162.8 million.
Return on equity averaged 12.4% over five years; 2024 ROE at 5.3%.
Outlook and guidance
2025 guidance: sales of €1.35–1.45 billion and EBITDA of €105–125 million, with margin expected to exceed 8%.
Dividend proposal increased from €0.17 to €0.75 per share for 2024.
Public sector expected to recover in H2 2025 after delayed budgets; SAP and IT services to offset weak automotive and manufacturing.
Ongoing market demand in IT services anticipated despite recessionary environment.
Latest events from adesso
- Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025 - 12% sales and 34% EBITDA growth in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 202518 Aug 2025